Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple supplement boost muscle strength before lung transplant?

NCT ID NCT07660991

Disease control Sponsor: Okan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether adding a dietary supplement called hydroxymethylbutyrate (HMB) to standard pulmonary rehabilitation helps lung transplant candidates improve muscle mass, strength, and overall health. Participants are adults aged 40-50 who are on the waiting list for a lung transplant. Half will receive HMB for 8 weeks alongside rehab and diet therapy, while the other half receive only rehab and diet therapy. The goal is to see if HMB can better prepare patients for surgery and recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hydroxymethylbutyrate (HMB)
What this could lead to
If it works, this could help lung transplant candidates maintain muscle mass and function before surgery, potentially improving recovery and quality of life.
What could go wrong
This is a small, early-stage study with only 30 participants, so results may not apply to everyone. HMB is generally safe but may not provide significant benefits over rehabilitation alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Jun 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who volunteer to participate in the study, * 40-50 years of age * BMI: 25.0kg/m² - 29.9kg/m² * Lung transplant candidates, * Suitable for pulmonary rehabilitation, * Suitable after consultation with psychiatrists, cardiologist, and orthopedists, * Hemodynamically stable, * Patients who have the ability to receive and follow instructions will be included. Exclusion Criteria: * Participants were excluded from the study if they were: • Not a lung transplant candidate * Not Turkish-speaking * Malnourished * Had a chronic disease such as diabetes, hypertension, cancer, metabolic syndrome, chronic renal failure, etc. * Were deemed ineligible after psychiatric, cardiological, or orthopedic consultations * Pregnant or breastfeeding * Used any oral nutritional supplement containing HMB before the study * Ineligible for pulmonary rehabilitation for any reason * Were found to be non-compliant with dietary/supplement interventions during follow-up after inclusion in the study. * Participants could withdraw from the study at any time during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lun transplant candidates are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lun transplant candidates Lung transplantation Pulmoner rehabilitation

Contacts and locations

Locations

  • Koşuyolu Yüksek Ihtisas Eğitim Ve Araştırma Hastanesi

    Istanbul, Kartal, 34865, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.